LY 404187 is a positive allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2). It enhances the activity of the receptor in response to glutamate, making it a valuable tool in neuroscience research, particularly in studies related to glutamatergic neurotransmission. Due to its ability to modulate synaptic glutamate levels, it has been investigated for potential therapeutic applications in psychiatric and neurological disorders, including schizophrenia, anxiety, and depression. Unlike direct agonists, LY 404187 offers a more subtle and physiologically regulated activation of mGluR2, which may lead to fewer side effects and better tolerability in long-term treatment strategies. Its use remains primarily in preclinical research to understand receptor function and evaluate pharmacological targets in animal models of brain disorders.